Related Experiment Videos
Benchmarking of growth hormone therapy in Hong Kong: ten-year data from the multi-centre GROWTH study
Antony Fu1, Malika Alimussina2, Jessica Anderson3
1Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong.
Objective:
To evaluate the local practice and short-term efficacy of recombinant human growth hormone (rhGH) therapy in children and adolescents in Hong Kong.
Methods:
A retrospective analysis of rhGH therapy in children and adolescents between 2013 and 2022 who attended six Hong Kong centres that had enrolled in GloBE-Reg.
Results:
The cohort comprised 161 males and 190 females with a range of clinical indications that consisted mainly of growth hormone deficiency (GHD) (n = 147, 41%). The median age at rhGH initiation was 10.1 years (range, 0.3, 18.1). Median one-year change in height standard deviation score (HtSDS) was available in 319 children (90.8%) and was 0.41 (range, -0.98, 3.4). The median starting dose of rhGH for GHD was 0.028 mg/kg/day (range, 0.008, 0.051).
Conclusions:
This multicentre study shows the utility of GloBE-Reg for understanding the use of rhGH therapy at a regional level. Findings demonstrate a variation in clinical practice as well as in short-term growth outcomes. These results support the need for continued optimisation of rhGH therapy through local benchmarking and care quality improvement activities.